Hutchmed China Skyrockets: $1.3B GSK Deal Boosts KRAS‑Targeted Therapy
Hutchmed China’s share price leaps after a $1.3 billion GSK licensing deal for its KRAS‑EGFR antibody drug, boosting investor confidence and global reach.
2 minutes to read
HUTCHMED CHINA